<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475241</url>
  </required_header>
  <id_info>
    <org_study_id>CDA-2-010-06F</org_study_id>
    <nct_id>NCT00475241</nct_id>
  </id_info>
  <brief_title>Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms</brief_title>
  <official_title>Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of the proposed research are to produce preliminary evidence of PE with OEF/OIF
      veterans with PTSD and to examine cognitive, psychophysiological, and neuroendocrine
      mechanisms of change in PTSD treatment. In brief, 36 OEF/OIF veterans with chronic PTSD or
      PTSS of at least 3 months duration will be randomly assigned to 15 sessions of either PE or
      TAU (see below for descriptions of the interventions). All veterans will receive
      psychobiological assessments at pre treatment, mid treatment, post treatment, 3 months, and 6
      months follow-up. Each of these assessments will cover in 2 sessions on separate days and
      will include interview and self-report of symptoms (i.e., PTSD, depression, and general
      anxiety severity), self-report of PTSD-related cognitions, psychophysiological (i.e., heart
      rate, skin conductance, respiration, and end-tidal CO2) assessment during neutral and trauma
      scripts, and assessment of salivary cortisol during neutral and trauma scripts. Also, on the
      morning prior to each laboratory assessment, patients will collect salivary cortisol at the
      moment of waking and 30 and 45 minutes post-walking. In addition to these assessments,
      patients assigned to PE will collect salivary cortisol during three imaginal exposure
      sessions (sessions 3, 9, and 15).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective treatments for PTSD are available, with exposure therapy (ET) programs, including
      Prolonged Exposure (PE), having the most empirical evidence for effectiveness (Rothbaum et
      al., 2000). However, among people receiving treatment for PTSD, many are not receiving
      psychotherapies with empirically proven efficacy. In one VA VISN, only 10% of PTSD specialist
      therapists reported using ET routinely (Rosen et al., 2004). They suggested that a lack of
      training and human resources to provide ET, as well as misconceptions about exposure therapy
      may drive the deficit. Training efforts would be substantially more cost-effective of the
      proven treatments could be delivered in group formats. Development and proof of efficacy of a
      group-based PE would provide far more veterans with access to a treatment that can truly
      foster recovery from the devastating impact of PTSD. This is a central goal of this proposal.

      Little is known about the mechanisms through which PE leads to recovery. Delineation of its
      mechanisms is a critical step towards the development of treatment refinements to improve
      effectiveness and efficiency of the treatment. We plan to examine the potential roles of
      cognitive, psychophysiologic and neuroendocrine factors in symptom improvement. The
      mechanistic component will provide preliminary data on interactions between cognitive change
      (increased sense of self-competence and control over negative outcomes), psychophysiological
      habituation (reduced reactivity to trauma related stimuli), and reduced neuroendocrine
      sensitivity (reduced hypothalamic-pituitary-adrenal (HPA) axis reactivity). We predict that
      cognitive change, psychophysiological habituation and reduced HPA reactivity will all be
      related to symptom improvement with effective treatment.

      Thirty-six OEF/OIF veterans with chronic PTSD of at least 3 months duration will be randomly
      assigned to 15 weeks of twice weekly PE-G or TAU. All veterans will receive psychobiological
      assessments at pre treatment, mid treatment, post treatment, 3 months and 6 months follow-up.
      Each of these assessments will include interview and self-report of symptoms (i.e., PTSD,
      depression, and general anxiety severity), self-report of PTSD-related cognitions,
      psychophysiological (i.e., heart rate, skin conductance, respiration, and end-tidal CO2)
      assessment during neutral and trauma scripts, and assessment of salivary cortisol during
      neutral and trauma scripts. Also, on the morning prior to each laboratory assessment,
      patients will collect salivary cortisol at the moment of waking and 30 and 45 minutes
      post-walking. The results from this study will be used as pilot data for VA Merit Award and
      NIMH R01 applications for larger follow-up studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (Pre &amp; Posttreatment)</measure>
    <time_frame>PostTreatment (Week 12)</time_frame>
    <description>Clinician Adminstered PTSD Scale (CAPS) assesses PTSD symptom severity. Scores range from 0 to 136 and higher scores represent more severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychophysiological Reactivity Will be Assessed Using a Biopac MP-100 Physiology Recording System for Measurement of Heart Rate (Electrocardiography, ECG), Skin Conductance, Respiration, and End-tidal pCO2 (Pre, Mid, Posttreatment, 3 and 6 mo FU).</measure>
    <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPA Axis Reactivity Will be Assessed With Collection of Salivary Cortisol at Each Major Assessment. Cortisol Response to Awakening, Our Measure of General Stress Reactivity, Will be Calculated.</measure>
    <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All of Below Measures Are Taken at the Major Assessment Points.- Beck Depression Inventory-II- Depression Anxiety Stress Scale- Posttraumatic Cognitions Inventory- Client Satisfaction Questionnaire</measure>
    <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Combat Disorders</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Prolonged Exposure Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prolonged exposure therapy for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Present Centered Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Present centered therapy for PTSD</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Exposure therapy for PTSD</intervention_name>
    <description>exposure-based treatment for PTSD</description>
    <arm_group_label>Prolonged Exposure Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Present centered therapy for PTSD</intervention_name>
    <description>present focused coping and problem solving for PTSD</description>
    <arm_group_label>Present Centered Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OEF/OIF Veterans with combat related posttraumatic stress disorder (PTSD) or
             posttraumatic stress symptoms (PTSS) of at least 3 months duration with significant
             impairment (PSSI greater than or equal to 15).

        Exclusion Criteria:

          -  Any current level of personality disorder or suicidal risk that in the judgment of the
             investigator makes it unlikely or contraindicated that the patient can adhere to the
             study regimen.

          -  Psychosis

          -  Alcohol or substance dependence in the past 3 months

          -  Working night-shifts

          -  Changes to psychoactive medication in the past 8 weeks

          -  Taking medication that makes HPA axis measures difficult to interpret
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Rauch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sripada RK, Rauch SA, Tuerk PW, Smith E, Defever AM, Mayer RA, Messina M, Venners M. Mild traumatic brain injury and treatment response in prolonged exposure for PTSD. J Trauma Stress. 2013 Jun;26(3):369-75. doi: 10.1002/jts.21813. Epub 2013 May 20.</citation>
    <PMID>23696427</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>October 27, 2014</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2014</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combat Disorders</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Posttraumatic Stress Disorder (PTSD)</keyword>
  <keyword>Psychophysiology</keyword>
  <keyword>Therapy</keyword>
  <keyword>Treatment</keyword>
  <keyword>Veterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Combat Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prolonged Exposure</title>
          <description>Prolonged exposure therapy for PTSD
Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD</description>
        </group>
        <group group_id="P2">
          <title>Present Centered Therapy</title>
          <description>Present centered therapy for PTSD
Present centered therapy for PTSD: present focused coping and problem solving for PTSD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prolonged Exposure</title>
          <description>Prolonged exposure therapy for PTSD
Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD</description>
        </group>
        <group group_id="B2">
          <title>Present Centered Therapy</title>
          <description>Present centered therapy for PTSD
Present centered therapy for PTSD: present focused coping and problem solving for PTSD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="6.5"/>
                    <measurement group_id="B2" value="32.9" spread="7.2"/>
                    <measurement group_id="B3" value="31.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAPS</title>
          <description>Clinician Adminstered PTSD Scale (CAPS) assesses PTSD symptom severity. Scores range from 0 to 136. Higher scores represent more severe symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.2" spread="12.1"/>
                    <measurement group_id="B2" value="77.4" spread="12.1"/>
                    <measurement group_id="B3" value="78.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale (Pre &amp; Posttreatment)</title>
        <description>Clinician Adminstered PTSD Scale (CAPS) assesses PTSD symptom severity. Scores range from 0 to 136 and higher scores represent more severe symptoms.</description>
        <time_frame>PostTreatment (Week 12)</time_frame>
        <population>Treatment Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Prolonged Exposure</title>
            <description>Prolonged exposure therapy for PTSD
Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD</description>
          </group>
          <group group_id="O2">
            <title>Present Centered Therapy</title>
            <description>Present centered therapy for PTSD
Present centered therapy for PTSD: present focused coping and problem solving for PTSD</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale (Pre &amp; Posttreatment)</title>
          <description>Clinician Adminstered PTSD Scale (CAPS) assesses PTSD symptom severity. Scores range from 0 to 136 and higher scores represent more severe symptoms.</description>
          <population>Treatment Completers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="18.4"/>
                    <measurement group_id="O2" value="53.6" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychophysiological Reactivity Will be Assessed Using a Biopac MP-100 Physiology Recording System for Measurement of Heart Rate (Electrocardiography, ECG), Skin Conductance, Respiration, and End-tidal pCO2 (Pre, Mid, Posttreatment, 3 and 6 mo FU).</title>
        <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPA Axis Reactivity Will be Assessed With Collection of Salivary Cortisol at Each Major Assessment. Cortisol Response to Awakening, Our Measure of General Stress Reactivity, Will be Calculated.</title>
        <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All of Below Measures Are Taken at the Major Assessment Points.- Beck Depression Inventory-II- Depression Anxiety Stress Scale- Posttraumatic Cognitions Inventory- Client Satisfaction Questionnaire</title>
        <time_frame>pre, mid, post, 3 and 6 mo FU</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prolonged Exposure</title>
          <description>Prolonged exposure therapy for PTSD
Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD</description>
        </group>
        <group group_id="E2">
          <title>Present Centered Therapy</title>
          <description>Present centered therapy for PTSD
Present centered therapy for PTSD: present focused coping and problem solving for PTSD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sheila A.M. Rauch</name_or_title>
      <organization>VA Ann Arbor Healthcare System</organization>
      <phone>734-845-3545</phone>
      <email>sherauch@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

